Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chemotherapy for multiple myeloma].

Tadao Ishida1

  • 1First Department of Internal Medicine, Sapporo Medical University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.

British journal of haematology·2026
Same author

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Clinical hematology international·2026
Same author

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study.

EJHaem·2026
Same author

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

Transplantation and cellular therapy·2026
Same author

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.

Blood·2026
Same author

A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database.

Therapeutic advances in hematology·2026
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Melphalan and prednisolone (MP) combination therapy is effective for multiple myeloma (MM). Combining MP with novel agents like thalidomide improves overall survival, potentially changing future MM treatment strategies.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Context:

  • Multiple myeloma (MM) treatment has evolved significantly since the introduction of melphalan and prednisolone (MP) in 1960.
  • Oral MP combination therapy demonstrates comparable efficacy to intravenous regimens.
  • Recent advancements include novel agents such as bortezomib, thalidomide, and liposomal doxorubicin.

Purpose:

  • To evaluate the efficacy of melphalan and prednisolone (MP) based regimens in multiple myeloma (MM).
  • To assess the impact of novel agents in combination with MP for MM treatment.
  • To review the evolving landscape of MM induction therapy.

Summary:

  • Melphalan and prednisolone (MP) combination therapy achieves objective responses in approximately 50% of multiple myeloma (MM) patients.

Related Experiment Videos

  • Meta-analysis confirms oral MP is as effective as intravenous combination regimens.
  • Combining MP with novel agents, particularly thalidomide, has shown significantly improved overall survival compared to MP alone.

    • Impact:

    • The findings suggest a paradigm shift in primary induction therapy for multiple myeloma.
    • Combination therapies involving novel agents offer improved survival outcomes for MM patients.
    • This research highlights the ongoing evolution of MM treatment strategies.